| 名稱 | EGFR WT （EGF Dependent）/BaF3 |
| 型號 | CBP73166 |
| 報價 |  |
| 特點 | EGFR WT （EGF Dependent）/BaF3,母細胞：BaF3，凍存條件：90% FBS+10% DMSO |
產品搜索
相關文章
聯系我們
產品展示 / PRODUCTS
藥靶細胞株 > kinase激酶細胞株 > CBP73166EGFR WT （EGF Dependent）/BaF3
- 詳細內容
| CBP73166 | |
| I. Introduction | |
Cell Line Name： | EGFR WT (EGF Dependent)/BaF3 |
Host Cell: | BA/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS+100ng/ml EGF |
Mycoplasma Status: | Negative |
| II.Background | |
EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section). In ligand-activated cancers, Cetuximab appears to be more effective than tyrosine-kinase inhibitors. | |
| III. Representative Data | |
1.WB of EGFR WT (EGF Dependent)/BaF3
| |
2. Anti-proliferation assay | |
Figure 2. CTG Proliferation Assay of EGFR WT(EGF Dependent) BaF3 cells (C16). | |
